Publication of First In-Human Data Reveals Safety Efficacy o...
BRISBANE, Australia, Dec. 9, 2019 /PRNewswire-AsiaNet/ -- - First in-human Clinical Phase I study of intratumoural tigilanol tiglate (EBC-46) has been published in The Lancet's EBioMedicine journal; - An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigila...
Authors: LATEST ASIANET NEWS RELEASES